Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 02, 2023 at 04:06 pm EDT
Share
Kura Oncology, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 38.6 million compared to USD 35.5 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.53 a year ago. Diluted loss per share from continuing operations was USD 0.5 compared to USD 0.53 a year ago.
For the nine months, net loss was USD 109.85 million compared to USD 102.73 million a year ago. Basic loss per share from continuing operations was USD 1.53 compared to USD 1.54 a year ago. Diluted loss per share from continuing operations was USD 1.53 compared to USD 1.54 a year ago.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.